Summary of Key Information:

Reporting Period: Quarter and half year ended 30 September 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated)

Date of Board Meeting / Approval: 6 November 2026

Audit Opinion: Unmodified review conclusion by Deloitte Haskins & Sells

Auditor's Comment: No material misstatement found; noted amalgamation accounting and unreviewed subsidiary financials

Key Financial Highlights [Amount in INR crores]

Standalone Results:

Revenue from Operations:

  • Q2 FY27: ₹1,204.21 crores (vs ₹681.81 crores in Q2 FY26, +76.6% YoY)
  • H1 FY27: ₹1,929.94 crores (vs ₹1,294.85 crores in H1 FY26, +49.1% YoY)

Total Income:

  • Q2 FY27: ₹1,250.33 crores
  • H1 FY27: ₹2,015.09 crores

Net Profit:

  • Q2 FY27: ₹106.15 crores
  • H1 FY27: ₹91.85 crores

EPS (Basic):

  • Q2 FY27: ₹1.29
  • H1 FY27: ₹1.37

Other Equity: ₹6,647.45 crores (vs ₹3,848.09 crores as of 31 March 2026)

Cash and Cash Equivalents: ₹174.58 crores (vs ₹119.44 crores as of 31 March 2026)

Debt:

  • Borrowings (Current + Non-current): ₹2,106.08 crores (vs ₹313.68 crores as of 31 March 2026)

Consolidated Results:

Revenue from Operations:

  • Q2 FY27: ₹2,829.20 crores (vs ₹1,197.21 crores in Q2 FY26, +136.3% YoY)
  • H1 FY27: ₹4,139.88 crores (vs ₹2,275.08 crores in H1 FY26, +82.0% YoY)

Total Income:

  • Q2 FY27: ₹2,880.73 crores
  • H1 FY27: ₹4,228.44 crores

Net Profit:

  • Q2 FY27: ₹322.38 crores
  • H1 FY27: ₹351.66 crores

EPS (Basic):

  • Q2 FY27: ₹3.19
  • H1 FY27: ₹4.14

Other Equity: ₹6,899.39 crores (vs ₹4,057.73 crores as of 31 March 2026)

Cash and Cash Equivalents: ₹776.15 crores (vs ₹228.07 crores as of 31 March 2026)

Debt:

  • Borrowings (Current + Non-current): ₹3,959.02 crores (vs ₹701.18 crores as of 31 March 2026)

Segment-wise Performance:

The Group revised its operating segment classification to two reportable segments:

Hospitals & Clinics:

  • Q2 FY27 Revenue: ₹2,772.84 crores
  • Q2 FY27 Segment Profit: ₹544.64 crores

Others:

  • Q2 FY27 Revenue: ₹112.91 crores
  • Q2 FY27 Segment Profit: ₹13.01 crores

Corporate Actions:

Amalgamation: Scheme of Amalgamation between Aster DM Healthcare Limited and Quality Care India Limited effective from 1 July 2026, approved by NCLT on 19 June 2026. Company name changed to Aster DM Quality Care Limited.

Share Allotment: Allotted 353,551,410 equity shares of ₹10 each to equity shareholders of erstwhile QCIL on 13 July 2026.

ESOP Scheme: Aster DM Quality Care Limited Employees Stock Option Scheme 2026 approved by Board on 30 January 2026 and shareholders on 26 September 2026.

Dividend: Paid dividend of ₹155.06 crores during H1 FY27.

Other Significant Information:

Entities Included: Consolidated results include 50 entities (parent, subsidiaries, joint venture, associates, and ESOP trust)

Auditor Reliance: Unaudited Consolidated Financial Results include financial information of 20 subsidiaries and ESOP trust not reviewed by their auditors, representing total assets of ₹3,697.42 crores

Balance Sheet Impact: Significant increase in assets and liabilities due to amalgamation, with total consolidated assets growing from ₹8,111.96 crores (31 March 2026) to ₹17,522.79 crores (30 September 2026)